Thales pioneers Post Quantum Cryptography with a successful world-first pilot on phone calls
24.2.2023 12:00:00 EET | Business Wire | Press release
Thales, as a worldwide cybersecurity leader, has created the first real-world application of Post Quantum Cryptography (PQC) in its flagship secure ‘Cryptosmart’ mobile app, leveraging 5G SIM for PQC. In the pilot, hybrid cryptography (pre and post quantum crypto) was used in a phone call between two devices to protect the information exchanged during the call. Thales has invested and tested post-quantum cybersecurity technologies over the last decade in order to prepare for these emerging threats.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230224005027/en/
Thales pioneers Post Quantum Cryptography with a successful world-first pilot on phone calls (Photo: Thales)
Even if today's quantum computer1 prototypes are still far from posing a threat to public key cryptography, it is critical to begin investigating resilient solutions. For example, there is a variant of "store now, decrypt later" attacks that consists in storing today's exchanged data and messages in order to decrypt these messages once Quantum Computers are available. This means the majority of digital infrastructure security based on public key cryptography (PKC) may already be vulnerable to a quantum attack.
Such threats are relevant for scenarios involving highly sensitive information, such as classified information exchanged over an encrypted phone call. To address these threats, Thales created a proof of concept to test the scalability and quality of its solutions, which range from 5G SIM cards to secure communication software.
This first real-world quantum protected mobile solution, which combines Thales' 'Cryptosmart' application and its 5G SIM, employs hybrid cryptography, as recommended by the NIST (National Institute of Standards and Technology). ‘CRYSTALS-Kyber’, one of the four algorithms selected by the NIST2, is the PQC algorithm natively implemented in the 5G SIM and used by Cryptosmart application to encrypt the communication.
“Building defences against threats that do not yet exist may appear to be a daunting task. That is exactly the prospect that the global cybersecurity community faces with the impending arrival of quantum computing. The post-quantum era is still years away, but as quantum computing becomes more prevalent, practicing crypto agility now with such pilots and trials are helping Thales and its customers get prepared” said Philippe KERYER, Executive Vice President Strategy & Technology at Thales.
1 Computers that can perform certain tasks much faster than today's computers on a large scale.
2
https://www.nist.gov/news-events/news/2022/07/nist-announces-first-four-quantum-resistant-cryptographic-algorithms
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations — connectivity, big data, artificial intelligence, cybersecurity and quantum computing — to build a future we can all trust, which is vital to the development of our societies.
The company provides solutions, services and products that help its customers —businesses, organisations and states — in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
Thales Digital Identity & Security
Thales unveils three quantum technologies set to revolutionise the world of tomorrow | Thales Group
Business Data Protection and Cybersecurity | Ercom
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230224005027/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
